Last updated: almost 2 years ago
AstraZeneca's Tagrisso Gains EU Approval: A Breakthrough for NSCLC Treatment
AstraZeneca's Tagrisso receives EU approval for NSCLC, showing 39.1 months PFS in LAURA trial. A game-changer for lung cancer patients with EGFR mutations.